THERAVEX Tissue Care Spray Plus for the Management of Cutaneous Wounds, Burns, and Chronic Ulcers

Overview

Pilot observational clinical evaluation assessing the safety and potential effectiveness of THERAVEX Tissue Care Spray Plus as an adjunctive topical therapy for the management of cutaneous wounds, burns, traumatic lesions, pressure ulcers, diabetic ulcers, and chronic ulcers in 26 patients. The study evaluated wound healing progression, epithelialization, tissue hydration, inflammatory response, tolerance, and overall clinical evolution in patients receiving standard wound care combined with topical application of THERAVEX Tissue Care Spray Plus. Preliminary observations demonstrated favorable tissue response, progressive epithelial regeneration, reduction of inflammatory signs, and absence of treatment-related adverse events.

Cutaneous wound healing is a complex biological process involving multiple coordinated phases including hemostasis, inflammation, cellular proliferation, angiogenesis, extracellular matrix remodeling, and epithelial regeneration. Various pathological conditions such as burns, diabetic ulcers, pressure ulcers, and traumatic wounds may impair this physiological healing cascade, resulting in delayed tissue repair, chronic inflammation, increased susceptibility to infection, and poor regenerative outcomes. Chronic wounds, particularly diabetic foot ulcers and pressure ulcers, represent a major global healthcare burden associated with significant morbidity, prolonged hospitalization, and elevated treatment costs. Impaired vascularization, persistent inflammatory activity, dysregulated fibroblast function, and altered extracellular microenvironment are recognized as key contributors to delayed wound healing. THERAVEX Tissue Care Spray Plus is a mineral-based topical bioactive formulation designed to support physiological tissue regeneration through modulation of the extracellular ionic microenvironment. The formulation aims to restore physicochemical conditions favorable for endogenous regenerative mechanisms, including epithelial migration, angiogenesis, tissue hydration, and extracellular matrix remodeling. This prospective pilot observational clinical evaluation investigated the safety and potential effectiveness of THERAVEX Tissue Care Spray Plus as an adjunctive topical therapy in the management of cutaneous wounds, burns, pressure ulcers, traumatic lesions, diabetic ulcers, and chronic ulcers. A total of 26 patients presenting with different types of cutaneous lesions were included in the observational evaluation. All patients received standard wound care management according to routine clinical practice combined with topical application of THERAVEX Tissue Care Spray Plus directly onto the wound surface following standard cleaning procedures. Clinical follow-up included periodic medical evaluation and photographic documentation during the healing process. The study assessed wound hydration, inflammatory signs, tissue appearance, granulation tissue formation, epithelialization progression, local tolerance, and adverse events associated with treatment. Preliminary clinical observations demonstrated progressive improvement in tissue hydration, reduction of inflammatory erythema, favorable granulation tissue formation, and progressive epithelial regeneration in the treated lesions. No treatment-related adverse reactions, allergic responses, or significant local intolerance were reported during the observation period. The results of this pilot observational evaluation suggest that THERAVEX Tissue Care Spray Plus may represent a biologically compatible supportive therapy for cutaneous wound management and tissue regeneration, supporting the need for further controlled clinical investigations in wound care and regenerative medicine.